SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the second quarter ended June 30, 2024. Company management will host a webcast and conference call on Monday, August 12, 2024, after the close of financial markets. Conference Call and Webcast Information Date: Monday, August 12, 2024 Time: 4:30 PM Eastern time / 1:30 PM Pacific time Con ...

Pharmacokinetic and tissue data confirm NaviCap platform delivers topically through the entire colon, with lower systemic concentrations, as desired Data modeling suggests tofacitinib tissue concentrations greater than IC90 through at least 16 hours after dosing SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, presented supplemental data from the Phase 1 trial of BT-600 during the company's virtual KOL event on Wednesd ...

A replay will be available online following the event. About Bruce Sands, MD, MS Bruce Sands, MD, MS is the Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York, NY. Dr. Sands was awarded his BA and MD from Boston University, and trained in internal medicine at the Hospital of the University of Pennsylvania. After completing GI fellowship at the Massachusetts General Hospital, he joined the faculty of Harvard Medical School and served as the Acting Chief of the ...

For more information, visit bioratherapeutics.com or follow the company on LinkedIn or Twitter. Biora Therapeutics expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. Media Contact media@bioratherapeutics.com Details of the presentation are as follows: Presentation Title: Empowering Peptide Self Administration with Needle-Free Smart Capsules Track: Pioneering Devices to Increase the Reach o ...

SAN DIEGO, May 20, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, presented a poster titled "Results of human device function studies for the NaviCap™ Targeted Oral Delivery Platform in healthy volunteers and patients with UC" at the Digestive Disease Week® conference in Washington DC, on Sunday, May 19, 2024. "In four separate clinical studies, we evaluated the functionality and safety of the NaviCap device in healthy particip ...

Biora Therapeutics, Inc. (NASDAQ:BIOR) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Chuck Padala - Managing Director, LifeSci Advisors Adi Mohanty - Chief Executive Officer Eric d'Esparbes - Chief Financial Officer Conference Call Participants Joseph Pantginis - H.C. Wainwright Rei Tan - BTIG John Vandermosten - Zacks Operator Greetings and welcome to Biora Therapeutics First Quarter 2024 Financial Results Call. At this time, all participants are in listen-only mode. A quest ...

Common Stock, par value $0.001 per share BIOR The Nasdaq Global Market ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 For the transition period from to Delaware 27-3950390 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Registrant's telephone number, including area code: (833) 727-2841 Indicate by check mark whether the registrant (1) has filed all reports required to ...

Biora Therapeutics Provides Corporate Update and Reports Dosing of all patients in clinical trial of BT-600 has been successfully completed, with results anticipated in late Q2 2024 Partnering process for the BioJet oral delivery platform is progressing well SAN DIEGO, May 15, 2024 – Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today provided a corporate update and reported financial results for the first quarter ended March 31, 2024. "We continue to ...

SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present clinical data on device function of the NaviCap™ Targeted Oral Delivery Platform at Digestive Disease Week® (DDW), which will take place both virtually and in-person May 18-21, 2024 in Washington, DC. Details of the presentations are as follows: Abstract Title:Results of Human Device Function Studies for the NaviCap™ Targeted O ...

All pharmacokinetic endpoints were achieved, with a PK profile consistent with drug delivery and absorption in the colon All NaviCap™ devices performed as intended and were well tolerated, with no safety signals observed Multiple-ascending dose (MAD) portion of the trial is underway and progressing well SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today shared additional positive interim results from the ...